Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113690 | 0.96 | SLC6A2 (0.54) | SLC6A2TAAR1LMNACYP2D6CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL28282036 | 0.93 | SLC6A2 (0.52) | SLC6A2TAAR1LMNACYP2D6CYP2C19 | |
| Acetic Acid SCHEMBL20515250 | 0.88 | HIF1A (0.47) | SLC6A2TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL11161013 | 0.84 | LMNA (0.54) | SLC6A2TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL2594091 | 0.81 | LMNA (0.42) | SLC6A2TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL29165440 | 0.81 | SLC6A2 (0.38) | SLC6A2TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL1572105 | 0.81 | SLC6A2 (0.64) | SLC6A2TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL1655425 | 0.80 | ALDH1A1 (0.47) | TAAR1LMNACYP2C19TSHRCYP2C9 | |
| SCHEMBL4352224 | 0.79 | SLC6A2 (0.56) | SLC6A2TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL11253564 | 0.78 | SLC6A2 (0.50) | SLC6A2TAAR1LMNACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2023-07-27 | — | — | US | claimed |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2020-11-05 | — | — | US | claimed |
| US-11744785-B2 | Use of volatile compositions to limit or eliminate the perception of malodor | FIRMENICH SA (CH) | 2023-09-05 | — | — | US | disclosed |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2023-07-27 | — | — | US | disclosed |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2020-11-05 | — | — | US | disclosed |
| EP-3541435-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE PERCEPTION OF FECAL MALODOUR | Firmenich SA (CH) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018091686-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE PERCEPTION OF FECAL MALODOUR | FIRMENICH SA (CH) | 2018-05-24 | — | — | WO | disclosed |
| EP-2063853-B1 | USE OF C10-C14-ALKANEDIOLS IN THE PREPARATION OF A COMPOSITION FOR THE PROPHYLAXIS AND/OR TREATMENT OF MALASSEZIA-INDUCED DANDRUFF FORMATION AND COMPOSITIONS COMPRISING C10-C14-ALKANEDIOLS | SYMRISE AG (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-8476318-B2 | Polyethylene glycol esters and cosmetic and/or dermatological preparations | SYMRISE AG (DE) | 2013-07-02 | — | — | US | disclosed |
| EP-2150247-B1 | POLYETHYLENE GLYCOL ESTERS AND COSMETIC AND/OR DERMATOLOGICAL PREPARATIONS | SYMRISE AG (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20100215775-A1 | USE OF C10-C14-ALKANEDIOLS IN THE PREPARATION OF A COMPOSITION FOR THE PROPHYLAXIS AND/OR TREATMENT OF MALASSEZIA-INDUCED DANDRUFF FORMATION | SYMRISE GMBH & CO. KG (DE) | 2010-08-26 | — | — | US | disclosed |
| US-20100150854-A1 | POLYETHYLENE GLYCOL ESTERS AND COSMETIC AND/OR DERMATOLOGICAL PREPARATIONS | SYMRISE GMBH & CO., KG (DE) | 2010-06-17 | — | — | US | disclosed |
| EP-2150247-A1 | POLYETHYLENE GLYCOL ESTERS AND COSMETIC AND/OR DERMATOLOGICAL PREPARATIONS | Symrise GmbH & Co. KG (DE) | 2010-02-10 | — | — | EP | disclosed |
| EP-2063853-A1 | USE OF C10-C14-ALKANEDIOLS IN THE PREPARATION OF A COMPOSITION FOR THE PROPHYLAXIS AND/OR TREATMENT OF MALASSEZIA-INDUCED DANDRUFF FORMATION AND COMPOSITIONS COMPRISING C10-C14-ALKANEDIOLS | Symrise GmbH & Co. KG (DE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008128892-A1 | POLYETHYLENE GLYCOL ESTERS AND COSMETIC AND/OR DERMATOLOGICAL PREPARATIONS | SYMRISE GMBH & CO. KG (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008046795-A1 | USE OF C10-C14-ALKANEDIOLS IN THE PREPARATION OF A COMPOSITION FOR THE PROPHYLAXIS AND/OR TREATMENT OF MALASSEZIA-INDUCED DANDRUFF FORMATION AND COMPOSITIONS COMPRISING C10-C14-ALKANEDIOLS | SYMRISE GMBH & CO. KG (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744785-B2 | Use of volatile compositions to limit or eliminate the perception of malodor | TAS2R8, TRPA1, TAS2R10 | MMP8 556/4885SLC6A2 1341/4885TAAR1 401/4885 |
| US-20100150854-A1 | POLYETHYLENE GLYCOL ESTERS AND COSMETIC AND/OR DERMATOLOGICAL PREPARATIONS | CUTA, LIPA, NAPEPLD | MMP8 1504/4885SLC6A2 4639/4885TAAR1 3346/4885 |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | MMP8 556/4885SLC6A2 1341/4885TAAR1 401/4885 |
| US-20100215775-A1 | USE OF C10-C14-ALKANEDIOLS IN THE PREPARATION OF A COMPOSITION FOR THE PROPHYLAXIS AND/OR TREATMENT OF MALASSEZIA-INDUCED DANDRUFF FORMATION | DECR2, DHCR24, CYP51A1 | MMP8 897/4885SLC6A2 4551/4885TAAR1 703/4885 |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | MMP8 556/4885SLC6A2 1341/4885TAAR1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.